Rheumatic Diseases Clinics of North America

[11]. Rikli RE, Edwards DJ. Effects of a three-year exercise program on motor function and cognitiveprocessing speed in older women. Res Q Exerc Sport 1991;62:61-7. Abstract[12]. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, Rutten-van Molken MP, Pelt RA, van Eek H, et al.Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. J Rheumatol1996;23:1237-45. Abstract[13]. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensoryprocessing in fibromyalgia. Mayo Clin Proc 1999;74:385-98. Abstract[14]. Friis S, Mellemkjaer L, McLaughlin JK, Breiting V, Kjaer SK, Blot W, et al. Connective tissue disease andother rheumatic conditions following breast implants in Denmark. Ann Plast Surg 1997;39:1-8. Abstract[15]. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporalsummation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165-75. Abstract[16]. Simms RW. Is there muscle pathology in fibromyalgia syndrome? Rheum Dis Clin North Am1996;22:245-66. Full Text[17]. Doubell TP, Mannion RJ, Woolf CJ. The dorsal horn: state-dependent sensory processing, plasticity andthe generation of pain. In: WallPD, MelzackR, editors. Textbook of pain London: Churchill Livingstone; 2000.p. 165-81.[18]. Willis Jr. WD. Dorsal horn neurophysiology of pain. Ann N Y Acad Sci 1988;531:76-89. Citation [19]. Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth 1995;75:193-200. Citation[20]. Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain 2000;16(3Suppl):S144-56. Abstract[21]. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-6.Abstract[22]. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinalfluid of patients with fibromyalgia. J Rheumatol 1999;26:1564-9. Abstract[23]. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluidlevels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601.Abstract[24]. Bennett RM. Pharmacological treatment of fibromyalgia. Journal of Functional Syndromes 2001;1:79-92. [25]. Bishop B. Pain: its physiology and rationale for management. Part I. Neuroanatomical substrate of pain.Phys Ther 1980;60:13-20. Abstract[26]. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. JClin Neurophysiol 1997;14:2-31. Abstract[27]. Willis Jr. WD. Anatomy and physiology of descending control of nociceptive responses of dorsal hornneurons: comprehensive review. Prog Brain Res 1988;77:1-29. Citation[28]. Hill R. NK1 (substance P) receptor antagonists–why are they not analgesic in humans? TrendsPharmacol Sci 2000;21:244-6. Abstract[29]. Graven-Nielsen T, Aspegren KS, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, et al. Ketaminereduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-91.Abstract[30]. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia: effects of intravenous morphine, lidocaine and ketamine. Scand J Rheumatol 1995;24:360-5.Abstract[31]. Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability infibromyalgia. J Rheumatol 1998;25:152-5. Abstract[32]. McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, et al. Dextromethorphan for thetreatment of neuropathic pain: a doubleblind randomised controlled crossover trial with integral n-of-1design. Pain 1994;59:127-33. Abstract[33]. Nelson KA, Park KM, Robinovitch E, Tsigos C, Max MB. High-dose oral dextromethorphan versusplacebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-8. Full Text[34]. Price DD, Mao J, Frenk H, Mayer DJ. The N-methyl-D-aspartate receptor antagonist dextromethorphanselectively reduces temporal summation of second pain in man. Pain 1994;59:165-74. Abstract[35]. Clark SR, Bennett RM. Supplemental dextromethorphan in the treatment of fibromyalgia: a double-blind, placebo-controlled study of efficacy and side-effects. Arthritis Rheum 2000;43(Suppl 9):S333.[36]. Harkins SW, Price DD, Braith J. Effects of extraversion and neuroticism on experimental pain, clinicalpain, and illness behavior. Pain 1989;36:209-18. Abstract[37]. Price DD, Harkins SW, Baker C. Sensory-affective relationships among different types of clinical andexperimental pain. Pain 1987;28:297-307. Abstract[38]. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anteriorcingulate but not somatosensory cortex. Science 1997;277:968-71. Abstract [39]. Turk DC. The role of psychological factors in chronic pain. Acta Anaesthesiol Scand 1999;43:885-8.Abstract[40]. Sharpe M, Carson A. “Unexplained” somatic symptoms, functional syndromes, and somatization: do weneed a paradigm shift? Ann Intern Med 2001;134:926-30. Abstract[41]. Haus U, Varga B, Stratz T, Späth M, Muller W. Oral treatment of fibromyalgia with tropisetron given over28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand JRheumatol 2000;(Suppl 113)55-8.[42]. Späth M, Welzel D, Farber L. Treatment of chronic fatigue syndrome with 5–HT3 receptor antagonists–preliminary results. Scand J Rheumatol 2000;(Suppl 113)72-7.[43]. Akerstedt T, Ficca G. Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours.Chronobiol Int 1997;14:145-58. Abstract[44]. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness innarcolepsy. Neurology 1997;49:444-51. Full Text[45]. Lyons TJ, French J. Modafinil: the unique properties of a new stimulant. Aviat Space Environ Med1991;62:432-5. Abstract[46]. Pigeau R, Naitoh P, Buguet A, McCann C, Baranski J, Taylor M, et al. Modafinil, d-amphetamine andplacebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995;4:212-28.[47]. Drewes AM, Gade K, Nielsen KD, Bjerregard K, Taagholt SJ, Svendsen L. Clustering of sleepelectroencephalographic patterns in patients with the fibromyalgia syndrome. Br J Rheumatol 1995;34:1151-6. Abstract [48]. Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am 1989;15:91-103. Abstract[49]. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleepstage deprivation. Psychosom Med 1976;38:35-44. Abstract[50]. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity,and attention to pain among women with fibromyalgia. Pain 1996;68:363-8. Abstract[51]. Goldenberg DL. A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome. JRheumatol 1989;(Suppl 19)137-9.[52]. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison ofcyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. ArthritisRheum 1988;31:1535-42. Abstract[53]. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of Amitriptyline,Cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994;37:32-40. Abstract[54]. Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology andsymptoms in patients with fibromyalgia. J Rheumatol 1991;18:452-4. Abstract[55]. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primaryfibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: A double-blind, placebo-controlled study. Arthritis Rheum 1991;34:552-60. Abstract[56]. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ. The effect of zolpidem in patients withfibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol1996;23:529-33. Abstract[57]. Drewes AM, Andreasen A, Jennum P, Nielsen KD. Zopiclone in the treatment of sleep abnormalities infibromyalgia. Scand J Rheumatol 1991;20:288-93. Abstract[58]. Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D. Effect of gamma-hydroxybutyrate on pain,fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol1998;25:1986-90. Abstract[59]. Montplaisir J, Lapierre O, Warnes H, Pelletier G. The treatment of the restless leg syndrome with or without periodic leg movements in sleep. Sleep 1992;15:391-5. Abstract[60]. Earley CJ, Yaffee JB, Allen RP. Randomized, double-blind, placebo-controlled trial of pergolide inrestless legs syndrome. Neurology 1998;51:1599-602. Full Text[61]. Inoue Y, Mitani H, Nanba K, Kawahara R. Treatment of periodic leg movement disorder and restless legsyndrome with talipexole. Psychiatry Clin Neurosci 1999;53:283-5. Abstract[62]. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved bypramipexole: a double-blind randomized trial. Neurology 1999;52:938-43. Full Text [63]. Gamsa A. The role of psychological factors in chronic pain. II. a critical appraisal. Pain 1994;57:17-29.Abstract[64]. Penny KI, Purves AM, Smith BH, Chambers WA, Smith WC. Relationship between the chronic paingrade and measures of physical, social and psychological well-being. Pain 1999;79:275-9. Abstract[65]. Goldenberg DL. Psychological symptoms and psychiatric diagnosis in patients with fibromyalgia. JRheumatol 1989;16(Suppl. 19):127-30.[66]. Hudson JI, Goldenberg DL, Pope Jr. HG, Keck Jr. PE, Schlesinger L. Comorbidity of fibromyalgia withmedical and psychiatric disorders. Am J Med 1992;92:363-7. Abstract[67]. Okifuji A, Turk DC, Sherman JJ. Evaluation of the relationship between depression and fibromyalgiasyndrome: why aren't all patients depressed? J Rheumatol 2000;27:212-9. Abstract[68]. Arnold LM, Keck Jr. PE, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis andreview. Psychosomatics 2000;41:104-13. Abstract[69]. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of themetabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord2000;24(Suppl 2):S50-5. Abstract[70]. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinologyof fibromyalgia. Arthritis Rheum 1997;40:1928-39. Citation[71]. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in thetreatment of fibrositis. J Rheumatol 1985;12:980-3. Abstract[72]. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with thefibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis Rheum 1992;35:1113-6.Abstract[73]. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-likegrowth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997;24:1384-9. Abstract[74]. Bennett RM, Clark SR, Walczyk J. A randomized, double-blind, placebo-controlled study of growthhormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31. Abstract[75]. Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystemfeatures of fibromyalgia. [editorial; comment] Semin Arthritis Rheum 2000;29:197-9. Citation[76]. Martinez-Lavin M, Hermosillo AG, Mendoza C, Ortiz R, Cajigas JC, Pineda C, et al. Orthostaticsympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997;24:714-8. Abstract[77]. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H. Dysautonomia among patients withfibromyalgia: a noninvasive assessment. J Rheumatol 2000;27:2660-5. Abstract[78]. Bou-Holaigah I, Calkins H, Flynn JA, Tunin C, Chang HC, Kan JS, et al. Provocation of hypotension andpain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 1997;15:239-46.Abstract[79]. Wilke WS, Fouad-Tarazi FM, Cash JM, Calabrese LH. The connection between chronic fatiguesyndrome and neurally mediated hypotension. Cleve Clin J Med 1998;65:261-6. Abstract[80]. Karas B, Grubb BP, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a potentiallytreatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents. Pacing ClinElectrophysiol 2000;23:344-51. Abstract[81]. Karas B, Grubb BP, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a potentiallytreatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents. Pacing ClinElectrophysiol 2000;23:344-51. Abstract[82]. Chase TN, Murphy DI. Serotonin and central nervous system function. Annu Rev Pharmacol Toxicol1983;13:181-97.[83]. Koltyn KF, Garvin AW, Gardiner RL, Nelson TF. Perception of pain following aerobic exercise. Med SciSports Exerc 1996;28:1418-21. Abstract[84]. Guieu R, Blin O, Pouget J, Serratrice G. Nociceptive threshold and physical activity. Can J Neurol Sci 1992;19:69-71. Abstract[85]. Goldfarb AH, Jamurtas AZ. Beta-endorphin response to exercise. An update. Sports Med 1997;24:8-16.Abstract [86]. Koltyn KF. Analgesia following exercise: a review. Sports Med 2000;29:85-98. Abstract[87]. Schwarz L, Kindermann W. Changes in beta-endorphin levels in response to aerobic and anaerobicexercise. Sports Med 1992;13:25-36. Abstract[88]. Bennett RM. The contribution of muscle to the generation of fibromyalgia symptomatology. JMusculoskeletal Pain 1996;4:35-59.[89]. Geel SE. The fibromyalgia syndrome: musculoskeletal pathophysiology. Semin Arthritis Rheum1994;23:347-53. Abstract[90]. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines ininflammation, illness responses and pathological pain states. Pain 1995;63:289-302. Abstract[91]. Jennum P, Drewes AM, Andreasen A, Nielsen KD. Sleep and other symptoms in primary fibromyalgiaand in healthy controls. J Rheumatol 1993;20:1756-9. Abstract[92]. Landro NI, Stiles TC, Sletvold H. Memory functioning in patients with primary fibromyalgia and majordepression and healthy controls. J Psychosom Res 1997;42:297-306. Abstract[93]. Sletvold H, Stiles TC, Landro NI. Information processing in primary fibromyalgia, major depression andhealthy controls. J Rheumatol 1995;22:137-42. Abstract [94]. Glass JM, Park DC. Cognitive dysfunction in fibromyalgia. Curr Rheumatol Rep 2001;3:123-7. Abstract[95]. Grace GM, Nielson WR, Hopkins M, Berg MA. Concentration and memory deficits in patients withfibromyalgia syndrome. J Clin Exp Neuropsychol 1999;21:477-87. Abstract [96]. Chapman CR, Gavrin J. Suffering: the contributions of persistent pain. Lancet 1999;353:2233-7.Abstract[97]. Menon PS, Gupta P, Karmarkar MG. High and low dose clonidine tests for the diagnosis of growthhormone deficiency. Indian Pediatr 1994;31:145-51. Abstract[98]. Sivri A, Cindas A, Dincer F, Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgiapatients. Clin Rheumatol 1996;15:283-6. Abstract[99]. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in theirritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999;94:3541-6. Abstract[100]. Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres BestPract Res Clin Gastroenterol 1999;13:461-71.[101]. Bennett RM, Clark SR, Campbell SM, Ingram SB, Burckhardt CS, Nelson DL, et al. Symptoms ofRaynaud's syndrome in patients with fibromyalgia. A study utilizing the Nielsen test, digitalphotoplethysmography, and measurements of platelet alpha 2-adrenergic receptors. Arthritis Rheum1991;34:264-9. Abstract[102]. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, andmultiple chemical sensitivities. Arch Intern Med 1994;154:2049-53. Abstract[103]. Jason LA, Taylor RR, Kennedy CL. Chronic fatigue syndrome, fibromyalgia, and multiple chemicalsensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms.Psychosom Med 2000;62:655-63. Abstract[104]. Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res2000;13:42-50. Abstract[105]. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: A comparative analysis. JRheumatol 1993;20:475-9. Abstract[106]. Jacobs JW, Rasker JJ, van der HA, Boersma JW, de Blecourt AC, Griep EN, et al. Lack of correlationbetween the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res 1996;9:105-11. Abstract[107]. Bennett RM, Burckhardt CS, Clark SR, O'Reilly CA, Wiens AN, Campbell SM. Group treatment offibromyalgia: a 6 month outpatient program. J Rheumatol 1996;23:521-8. Abstract[108]. King S, Wessel J, Bhambhani Y, Maikala R, Sholter D, Maksymowych W. Validity and reliability of the 6minute walk in persons with fibromyalgia. J Rheumatol 1999;26:2233-7. Abstract[109]. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development andvalidation. J Rheumatol 1991;18:728-33. Abstract[110]. Goldenberg DL, Mossey CJ, Schmid CH. A model to assess severity and impact of fibromyalgia. J Rheumatol 1995;22:2313-8. Abstract[111]. Worrel LM, Krahn LE, Sletten CD, Pond GR. Treating fibromyalgia with a brief interdisciplinary program:initial outcomes and predictors of response. Mayo Clin Proc 2001;76:384-90. Abstract[112]. Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinicaltrial outcome measures. J Rheumatol 2000;27:2683-91. Abstract